Molecular Partners News

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

17.12.24	Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January (GlobeNewswire)
08.12.24	Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024 (GlobeNewswire)
07.11.24	Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024 (GlobeNewswire)
05.11.24	Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition (GlobeNewswire)
31.10.24	Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going (GlobeNewswire)
25.10.24	Molecular Partners Announces Pricing of $20 Million Underwritten Offering (GlobeNewswire)
22.10.24	Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics (GlobeNewswire)
22.10.24	Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024 (GlobeNewswire)
04.10.24	Molecular Partners Announces upcoming poster presentations at the 2024 SITC Annual Meeting (GlobeNewswire)
27.09.24	Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 202 (GlobeNewswire)
26.08.24	Molecular Partners Reports H1 2024 Corporate Highlights and Financials (GlobeNewswire)
14.06.24	Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024 (GlobeNewswire)
11.06.24	Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024 (GlobeNewswire)
19.04.24	Life Science Cares Launches in Switzerland (GlobeNewswire)
19.12.18	MOLECULAR PARTNERS AND AMGEN ANNOUNCE STRATEGIC COLLABORATION IN IMMUNO-ONCOLOGY (Tensid)
06.12.18	Molecular Partners’ R&D Day in New York highlights progress of pipeline of DARPin® therapeutic candidates and dedicated research focus areas (Tensid)
01.11.18	INTERIM MANAGEMENT STATEMENT Q3 2018 (Tensid)
29.10.18	Abicipar phase 3 data presented at AAO Conference in Chicago: Potential to be the first fixed 12-week anti-VEGF therapeutic (Tensid)
30.08.18	Molecular Partners reports key financials for H1 18 and corporate highlights for the second quarter 2018: Promising MP0250 clinical data in oncology and positive abicipar phase 3 efficacy data... (Tensid)
19.07.18	Allergan and Molecular Partners Announce Two Positive Phase 3 Clinical Trials for Abicipar pegol 8 and 12-week Regimens for the Treatment in Patients with Neovascular Age-Related Macular Degeneration (Tensid)
21.06.18	Molecular Partners Appoints Pamela A. Trail as Chief Scientific Officer; Michael T. Stumpp Assumes Role of Chief Operating Officer of the Company (Tensid)
15.06.18	Molecular Partners presents updated results from its ongoing Phase 2 combination study of its lead oncology drug MP0250 at EHA in Stockholm (Tensid)
16.05.18	Molecular Partners to present final MP0250 Phase 1 data at ASCO Annual Meeting 2018 (Tensid)
26.04.18	INTERIM MANAGEMENT STATEMENT Q1 2018 (Tensid)
21.04.18	Molecular Partners presented preliminary results from the ongoing phase 2 study of MP0250 at the European Myeloma Network Meeting in Turin (Tensid)
18.04.18	Shareholders of Molecular Partners AG approve all Board proposals at the Annual General Meeting – Bill Burns elected new Chairman (Tensid)
11.04.18	Molecular Partners and AstraZeneca announce collaboration on Molecular Partners’ ongoing oncology clinical study with MP0250 in EGFR-mutated NSCLC (Tensid)
05.04.18	Molecular Partners to present MP0310 pre-clinical data and MP0250 clinical abstracts at the AACR Annual Meeting 2018 (Tensid)
21.03.18	Molecular Partners Publishes Invitation to Annual General Meeting 2018 (Tensid)
16.03.18	Molecular Partners Publishes Audited Financial Results and Annual Report 2017 (Tensid)
19.02.18	Molecular Partners’ collaboration partner Allergan exercises the third option for a DARPin® product candidate in ophthalmology (Tensid)
08.02.18	Molecular Partners reports significant progress of pipeline and preliminary unaudited key financials for 2017 - Key value inflection points in 2018 (Tensid)
08.01.18	Molecular Partners reports promising initial safety and efficacy data from its ongoing phase 2 study of MP0250 in multiple myeloma (Tensid)
03.01.18	Molecular Partners’ collaboration partner Allergan exercises options for two DARPin® product candidates (Tensid)
09.11.17	Molecular Partners expands and advances robust pipeline of DARPin ® therapies in oncology and ophthalmology (Tensid)
31.10.17	Shareholders of Molecular Partners approved the elections of Bill Burns and Patrick Amstutz to the Board of Directors (Tensid)
26.10.17	Significant progress across all clinical programs – New pre-clinical immuno-oncology data to be presented during R&D Day in New York (Tensid)
12.10.17	First patient dosed in phase 1 clinical study of Molecular Partners’ second proprietary oncology asset MP0274 (Tensid)
09.10.17	Molecular Partners Publishes Invitation to Extraordinary General Meeting to be held on October 31, 2017 (Tensid)
03.10.17	Bill Burns nominated for election to Molecular Partners’ Board of Directors as Vice-Chairman with nomination to Chairman in 2018 (Tensid)
30.08.17	Molecular Partners reports key financials and corporate highlights for H1 2017: Pipeline development on track with several key milestones ahead (Tensid)
30.05.17	Molecular Partners provides additional details on clinical studies of proprietary lead oncology asset MP0250 (Tensid)
12.05.17	Patrick Amstutz Appointed as Chief Executive Officer (Tensid)
11.05.17	Shareholders of Molecular Partners AG approved all Board proposals at the Annual General Meeting - Gwen Fyfe elected new Board member (Tensid)
09.05.17	Molecular Partners’ strategic partner Allergan completed patient recruitment in both abicipar pegol nAMD Phase 3 studies (Tensid)
04.05.17	Quarterly Management Statement for the Period Ending March 31, 2017 (Tensid)
13.04.17	Molecular Partners Publishes Invitation to Annual General Meeting 2017 (Tensid)
12.04.17	Christian Zahnd appointed as Honorary Chairman of the Board of Directors as he decided not to stand for re-election as member of the Board of Directors at the Annual General Meeting 2017 (Tensid)
06.04.17	Molecular Partners discloses change in shareholder base (Tensid)
31.03.17	Molecular Partners Publishes Audited Financial Results and Annual Report 2016 (Tensid)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

mehr

27.12.24		SPI aktuell: SPI zum Ende des Freitagshandels in der Gewinnzone
23.12.24		Starker Wochentag in Zürich: SPI verbucht Gewinne
23.12.24		Angespannte Stimmung in Zürich: SPI zum Handelsstart schwächer
20.12.24		SPI-Handel aktuell: SPI zum Handelsende leichter
17.12.24		Dienstagshandel in Zürich: SPI liegt zum Start des Dienstagshandels im Minus
16.12.24		Gute Stimmung in Zürich: SPI zum Handelsstart mit grünem Vorzeichen
13.12.24		Schwacher Wochentag in Zürich: SPI fällt zum Start
11.12.24		Pluszeichen in Zürich: SPI letztendlich fester